if VP-001 succeeds along with upcoming program… we’ll probably be the first player in the world to create a CPP-PMO therapeutic platform across multiple modalities@Linsanity
VP-001 could be life changing for people with Retinitis Pigmentosa Type 11. It will also be a proof of concept for the delivery technology which will establish the utility of the CPP-PMO platform in genetic medicines. Slide 6 from the AGM pack of slides highlights the opportunity - the delivery of enough drug to the target to overcome the primary challenge for genetic medicines.
The discussion around the 25% share issuance capacity arranged by the company to accommodate potential partners makes sense in light of the imminent entry to the clinic. The resolution of the delivery problem for RNA therapies would arouse major international interest in the platform. The question is whether it would arouse interest or has aroused interest? Either way, its an exciting time to be a shareholder.
PYC Price at posting:
6.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)